The short answer
A small trial that included enalapril users did not find extra blood-pressure lowering from high-dose fish oil compared with olive oil. That limits the blanket warning that this combination causes low pressure, but does not prove it is safe for everyone. Review the exact product and your blood-pressure history with your clinician.
What this answer covers
Oral omega-3 products with oral enalapril, focusing on fish oil supplying EPA and DHA. Evidence from fish oil is not automatically assigned to ALA, every algal product or a prescription omega-3 formulation.
- Supplement or preparation
- omega-3
- Medication ingredient
- enalapril
What did the most relevant trial find?
The trial included 56 people taking either enalapril or captopril. Over six weeks, fish oil supplying 5 g of omega-3 fatty acids daily did not lower blood pressure more than olive oil. Lower sodium intake did produce an additional reduction. Because the results combined both medicines, they do not provide a separate estimate for enalapril.
Does that rule out low blood pressure?
No. The study’s average blood-pressure result does not establish how every person will respond or quantify episodes of symptomatic hypotension. Enalapril itself can cause excessive lowering, particularly in people with heart failure or salt or fluid depletion. A new episode of lightheadedness still needs attention, whatever the presumed cause.
Why does the product label matter?
The total weight of fish oil is not the same as its EPA and DHA content. Omega-3 products also differ in source and formulation, and plant ALA is a different exposure. The high dose used in this trial is a study detail, not a recommended amount to take with enalapril.
Should you change how you take them?
Do not change prescribed enalapril or prescription omega-3 treatment solely because of a generic warning. Bring the supplement label, dose, usual blood-pressure readings and symptoms to a medication review. No protective spacing interval for this combination was established in the inspected evidence.
Evidence and practical considerations
Physiologic interactions
The inspected mixed-ACE-inhibitor trial found no additional average blood-pressure lowering from fish oil. Evidence is insufficient to establish increased hypotension risk specifically with enalapril, and this neutral trial does not prove absence of risk.
- Exact scope
- Oral omega-3 products with oral enalapril, focusing on fish oil supplying EPA and DHA. Evidence from fish oil is not automatically assigned to ALA, every algal product or a prescription omega-3 formulation. with Enalapril, RxCUI 3827, IN. Oral enalapril maleate tablets are an explicitly identified salt formulation of enalapril in the label. This bridge applies to the labeled oral prodrug; injected enalaprilat, other ACE inhibitors and combination products are not assigned this evidence automatically.
- Medication form and route
- oral
What remains uncertain
- One small six-week trial pooled enalapril and captopril users. The abstract does not provide enalapril-only or symptomatic-hypotension outcomes. No universal safe dose, clinical benefit or spacing rule follows from its result.
Factors that may matter: EPA/DHA content; mixed-drug study results; baseline blood pressure; heart failure or fluid depletion.
Read the supporting source summaries
Source 1: original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 56 people with hypertension taking either captopril or enalapril, divided into four matched groups.
The fish-oil and olive-oil groups did not differ in blood pressure. Sodium restriction, rather than fish oil, produced the additional systolic reduction.
How this applies: Includes the exact medication in a mixed-drug population. This neutral finding limits the broad high-dose warning; it does not establish safety for every product or patient.
Original abstract only. Enalapril-specific results are not separated from captopril, and symptomatic hypotension risk is not quantified. A neutral average does not rule out individual adverse effects.
Source 2: government supplement reference
nccih.nih.gov · Source check Sep 10, 2026
Population: People using or considering omega-3 products.
Distinguishes omega-3 types and product sources and advises discussing supplements with a health professional, especially when medicines are used.
How this applies: Supports reading the EPA/DHA content and exact formulation instead of equating total fish-oil weight, ALA and prescription products.
Not a trial of omega-3 with enalapril and not proof that a particular dose causes hypotension.
Source 3: regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral enalapril maleate for hypertension or heart failure.
Excessive hypotension is uncommon in uncomplicated hypertension but is a recognized risk, especially with heart failure or salt or fluid depletion. Patients should report lightheadedness and conditions causing dehydration.
How this applies: The maleate formulation is explicitly identified as a salt of enalapril. Applies to oral enalapril, RxCUI 3827 IN; does not transfer to injected enalaprilat or another ACE inhibitor.
Provides the exact medication context. It does not establish an interaction with any of the supplements assessed in this batch or a dose-separation rule.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Sources checked and original article drafted. Exact medicine, preparation and study limits are recorded for review. | |
| Research summary published |
Article revision: 1f0920ef18a568ff
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.